GHRP-2 vs Sermorelin
A side-by-side research comparison of GHRP-2 and Sermorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GHRP-2 | Sermorelin |
|---|---|---|
| Full name | Growth Hormone Releasing Peptide-2 (Pralmorelin) | Sermorelin Acetate (GHRH 1-29) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Previously FDA-approved (discontinued 2008) |
| Mechanism | Potent GHSR-1a agonist stimulating GH release and appetite. Also mildly stimulates ACTH/cortisol release. | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. |
| Molecular weight | 818 Da | 3,358 Da |
| Half-life | 1-2 hours | 10-20 minutes |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 100-300 mcg | 200-300 mcg |
| Frequency | 2-3x daily | Once daily before bed |
| Route | Subcutaneous | Subcutaneous injection |
GHRP-2 reported benefits
- Strongest GH release among GHRPs
- Appetite stimulation
- Recovery improvement
- Enhanced sleep
- Muscle preservation
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Related comparisons
Research and educational reference only. Not medical advice.